Asthma Therapeutics - Global Strategic Business Report - Market Research Reports

Contents:

ASTHMA THERAPEUTICS
A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability And Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions And Scope Of Study I-3
Inhaled Corticosteroids: I-3
Beta-2 Adrenoreceptor Agonists I-4
Combinations I-4
Anti- leukotrienes I-4
Others I-4
Antihistamines I-4
Methylxanthines I-4
Mast Cell Stabilizers I-5
Monoclonal Antibodies I-5
Anticholinergics I-5

II.
1. Market Overview II-1
Current & Future Analysis II-1
Competitive Outlook II-1
Major Asthma Therapeutics by Class II-2
Facts about Asthma II-2

2. Trends & Issues II-3
Combination Drugs
Rule the World II-3
Novel Compounds To Pep Up Growth II-3
Rise in Pediatric Asthma To Keep Market Lucrative II-3
Toxic Nature of Asthma Drugs
A Serious Concern II-3
Life Threatening Drugs Under Regulatory Scan II-3

3. Product Overview II-4
Causes of Asthma II-4
Allergens II-4
Irritants II-4
Other Factors II-4
Classes in Asthma II-5
A. Mild Intermittent Asthma: II-5
B. Mild Persistent Asthma: II-5
C. Moderate Persistent Asthma: II-5
D. Severe Persistent Asthma: II-5
Asthma Treatments II-6
Combination Asthma Medications II-6
Over-the-Counter Asthma Medications II-6
Immunotherapy (Allergy shots) II-6
Alternative Therapies II-6
Asthma Therapeutics II-6
Corticosteroids II-7
Beta-2 Adrenoreceptor Agonists II-7
Mast Cell Stabilizers II-7
Monoclonal Antibodies II-7
Immune System: Natural Defenders II-7
Human Antibodies II-8
Polyclonal and Monoclonal Antibodies II-8
Leukotriene Inhibitors II-8
Methylxanthines: II-8
Combination Therapeutics: II-8
Off Label Therapeutics: II-8
Anticholinergics: II-8
Antihistamines: II-9
Asthma Therapeutics by Various Classes II-9

4. Product Launches/Innovations II-10
Future to Witness A Novel Therapeutic in Asthma Treatment II-10
Dr. Reddy’s Releases Doxobid in India II-10
Novartis Files Approval for Xolair to Enter Japanese Market II-10
AstraZeneca Receives Approval for Symbicort II-10
GSK Alters Labels for Two Asthma Drugs II-10
DMI BioSciences Starts Evaluating DMI 8393 II-11
Inflazyme Begins Phase IIb Trial for IPL512,602 II-11
Neurim Develops A Neuroprotective Compound II-11
Xolair® Forays into UK II-11
Critical Therapeutics Rolls Out ZYFLO® II-11
Ivax Corp. Introduces Qvar EasiBreathe Inhaler II-12
Altana Rolls Out Respiratory Drug, Alvesco in the UK II-12
Sepracor Launches XOPENEX HFA II-12
Polyphor Commences Research for Protease Inhibitors II-12
Novartis Plans to Apply for A New Drug Approval II-12
Asmanex Twisthaler 220 mcg Receives US FDA Approval II-12
GroPep Completes Pre-Clinical Testing of T-Cell Peptide Drug II-13
Able Laboratories Obtains FDA Approval II-13
Acceleration Therapeutics’ AT-101 Passes Laboratory Test II-13
Pharmaxis’ New Tool to Assess Asthma Passes Clinical Trial II-13
Aventis Seeks FDA Approval Alvesco® II-13
Schering-Plough Releases Asmanex Twisthaler II-13
FDA Clears Xolair to Enter US Market II-14
Sepracor Completes Phase III Trial for XOPENEX II-14
Pfizer Conducts Phase II Clinical Studies II-14
Celera and Bayer Plans to End Collaboration II-14
Banyu and Kyorin Starts Distribution of Asthma Treatment II-14
GlaxoSmithKline Introduces Advair II-14
Novartis Gets FDA Approval for Foradil Aerolizer II-14

5. Recent Industry Activity II-15
Teva Purchases Ivax II-15
SkyePharma Strikes A Deal with KOSP II-15
Ranbaxy Inks an In-Licensing Agreement with Eurodrug II-15
Pfizer and Rigel Forms A Collaboration II-15
MAP and Elan Extends Agreement II-15
Glenmark Collaborates with Teijin Pharma II-16
Pfizer Acquires Meridica II-16
Bayer and Apax Forms A New Company II-16
KOSP Signs Multiple Agreements II-16
Novartis Pharma Inks A Licensing Agreement with Ivax II-17
LAB Intends to Purchase Seyvika II-17
ALTANA and Tanabe Signs A Pact II-17

6. Focus on Select Players II-18
Abbott Laboratories (US) II-18
ALTANA Pharma AG (Germany) II-18
AstraZeneca (UK) II-18
Boehringer Ingelheim (Germany) II-19
Genentech, Inc. (US) II-19
GlaxoSmithKline (UK) II-19
Merck & Co., Inc. (US) II-19
Novartis Pharma AG (Switzerland) II-19
Pfizer Inc. (US) II-20
Schering-Plough Corporation (US) II-20
Sepracor Inc. (US) II-20
The Sanofi-Aventis Group (US) II-21
3M (US) II-21

7. Global Market Perspective II-22
Table 1: World Recent Past, Current and Future Analysis for
Asthma Therapeutics by Geographic Region
US, Canada, Japan,
Europe and Rest of World Markets Independently Analyzed by
Annual Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) II-22

Table 2: World 10-Year Perspective for Asthma Therapeutics by
Geographic Region
Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe and Rest of World Markets for the
Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-22

Table 3: World Recent Past, Current and Future Analysis for
Inhaled Corticosteroids by Geographic Region
US, Canada,
Japan, Europe and Rest of World Markets Independently Analyzed
by Annual Sales for the Years 2000 through 2010 in US$
Million (includes corresponding Graph/Chart) II-23

Table 4: World 10-Year Perspective for Inhaled Corticosteroids
by Geographic Region
Percentage Breakdown of Dollar Sales
for US, Canada, Japan, Europe and Rest of World Markets for
the Years 2000, 2006 and 2010 (includes corresponding Graph/
Chart) II-23

Table 5: World Recent Past, Current and Future Analysis for
Short Acting Beta Agonists by Geographic Region
US, Canada,
Japan, Europe and Rest of World Markets Independently Analyzed
by Annual Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) II-24

Table 6: World 10-Year Perspective for Short Acting Beta
Agonists by Geographic Region
Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe and Rest of World Markets
for the Years 2000, 2006 and 2010 (includes corresponding
Graph/Chart) II-24

Table 7: World Recent Past, Current and Future Analysis for
Long Acting Beta Agonists by Geographic Region
US, Canada,
Japan, Europe and Rest of World Markets Independently Analyzed
by Annual Sales for the Years 2000 through 2010 in US$
Million (includes corresponding Graph/Chart) II-25

Table 8: World 10-Year Perspective for Long Acting Beta
Agonists by Geographic Region
Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe and Rest of World
Markets for the Years 2000, 2006 and 2010 (includes
corresponding Graph/Chart) II-25

Table 9: World Recent Past, Current and Future Analysis for
Combinations by Geographic Region
US, Canada, Japan, Europe
and Rest of World Markets Independently Analyzed by Annual
Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) II-26

Table 10: World 10-Year Perspective for Combinations by
Geographic Region
Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe and Rest of World Markets for the
Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-26

Table 11: World Recent Past, Current and Future Analysis for
Anti-Leukotrienes by Geographic Region
US, Canada, Japan,
Europe and Rest of World Markets Independently Analyzed by
Annual Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) II-27

Table 12: World 10-Year Perspective for Anti-Leukotrienes by
Geographic Region
Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe and Rest of World Markets for the
Years 2000, 2006 and 2010 (includes corresponding Graph/
Chart) II-27

Table 13: World Recent Past, Current and Future Analysis for
Other Asthma Therapeutics by Geographic Region
US, Canada,
Japan, Europe and Rest of World Markets Independently Analyzed
by Annual Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) II-28

Table 14: World 10-Year Perspective for Other Asthma
Therapeutics by Geographic Region
Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe and Rest of World
Markets for the Years 2000, 2006 and 2010 (includes
corresponding Graph/Chart) II-28

III. MARKET

1. The United States III-1
A.Market Analysis III-1
Current & Future Analysis III-1
Asthma Reflections in the US III-1
Competitive Scenario III-1
Table 15: Leading Anticholinergic Companies in the US
(2006): Percentage Breakdown of Market Share for Boehringer
Ingelheim, Dey Inc, Alpharma and Others (includes
corresponding Graph/Chart) III-1
Product Launches/Innovations III-2
Strategic Developments III-4
Focus on Key Players III-5
3M III-5
Abbott Laboratories III-5
Genentech, Inc. III-5
Merck & Co., Inc. III-6
Pfizer Inc. III-6
Schering-Plough Corporation III-6
Sepracor Inc. III-6
The Sanofi-Aventis Group III-7
B.Market Analytics III-8
Table 16: US Recent Past, Current and Future Analysis for
Asthma Therapeutics by Product Segment
Inhaled
corticosteroids, Short acting beta agonists, Long acting
beta agonists, Combinations, Anti- leukotrienes and Other
Asthma Therapeutics Markets Independently Analyzed by Annual
Sales for the Years 2000 through 2010 in US$ Million (
includes corresponding Graph/Chart) III-8

Table 17: US 10-Year Perspective for Asthma Therapeutics by
Product Segment
Percentage Breakdown of Dollar Sales for
Inhaled corticosteroids, Short acting beta agonists, Long
acting beta agonists, Combinations, Anti- leukotrienes and
Other Asthma Therapeutics Markets for the Years 2000, 2006
and 2010 (includes corresponding Graph/Chart) III-9

2. Canada III-10
A.Market Analysis III-10
Current & Future Analysis III-10
Product Launches/Innovations III-10
Strategic Development III-10
B.Market Analytics III-11
Table 18: Canadian Recent Past, Current and Future Analysis
for Asthma Therapeutics by Product Segment
Inhaled
corticosteroids, Short acting beta agonists, Long acting
beta agonists, Combinations, Anti- leukotrienes and Other
Asthma Therapeutics Markets Independently Analyzed by Annual
Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) III-11

Table 19: Canadian 10-Year Perspective for Asthma
Therapeutics by Product Segment
Percentage Breakdown of
Dollar Sales for Inhaled corticosteroids, Short acting beta
agonists, Long acting beta agonists, Combinations, Anti-
leukotrienes and Other Asthma Therapeutics Markets for the
Years 2000, 2006 and 2010 (includes corresponding Graph/
Chart) III-12

3. Japan III-13
A.Market Analysis III-13
Current & Future Analysis III-13
Product Approvals/Launches III-13
Strategic Developments III-13
B.Market Analytics III-14
Table 20: Japanese Recent Past, Current and Future Analysis
for Asthma Therapeutics by Product Segment
Inhaled
corticosteroids, Short acting beta agonists, Long acting
beta agonists, Combinations, Anti- leukotrienes and Other
Asthma Therapeutics Markets IndependentlyAnalyzed by Annual
Sales for the Years 2000 through 2010 in US$ Million (
includes corresponding Graph/Chart) III-14

Table 21: Japanese 10-Year Perspective for Asthma
Therapeutics by Product Segment
Percentage Breakdown of
Dollar Sales for Inhaled corticosteroids, Short acting beta
agonists, Long acting beta agonists, Combinations, Anti-
leukotrienes and Other Asthma Therapeutics Markets for the
Years 2000, 2006 and 2010 (includes corresponding Graph/
Chart) III-15

4. Europe III-16
Market Analysis III-16
Current & Future Analysis III-16
Table 22: European Recent Past, Current and Future Analysis
for Asthma Therapeutics by Geographic Region
France,
Germany, UK, Italy, Spain and Rest of Europe Independently
Analyzed by Annual Sales for the Years 2000 through 2010 in
US$ Million (includes corresponding Graph/Chart) III-16

Table 23: European Recent Past, Current and Future Analysis
for Asthma Therapeutics by Product Segment
Inhaled
corticosteroids, Short acting beta agonists, Long acting
beta agonists, Combinations, Anti- leukotrienes and Other
Asthma Therapeutics Markets Independently Analyzed by Annual
Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) III-17

Table 24: European 10-Year Perspective for Asthma
Therapeutics by Geographic Region
Percentage Breakdown of
Dollar Sales for France, Germany, UK, Italy, Spain and Rest
of Europe for the Years 2000, 2006 and 2010 (includes
corresponding Graph/Chart) III-18

Table 25: European 10-Year Perspective for Asthma
Therapeutics by Product Segment
Percentage Breakdown of
Dollar Sales for Inhaled corticosteroids, Short acting beta
agonists, Long acting beta agonists, Combinations, Anti-
leukotrienes and Other Asthma Therapeutics Markets for the
Years 2000, 2006 and 2010 (includes corresponding Graph/
Chart) III-19

4a. France III-20
Market Analysis III-20
Current & Future Analysis III-20
Table 26: French Recent Past, Current and Future Analysis
for Asthma Therapeutics by Product Segment
Inhaled
corticosteroids, Short acting beta agonists, Long acting
beta agonists, Combinations, Anti- leukotrienes and Other
Asthma Therapeutics Markets Independently Analyzed by Annual
Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) III-20

Table 27: French 10-Year Perspective for Asthma Therapeutics
by Product Segment
Percentage Breakdown of Dollar Sales
for Inhaled corticosteroids, Short acting beta agonists,
Long acting beta agonists, Combinations, Anti- leukotrienes
and Other Asthma Therapeutics Markets for the Years 2000,
2006 and 2010 (includes corresponding Graph/Chart) III-21

4b. Germany III-22
A.Market Analysis III-22
Current & Future Analysis III-22
Product Launches/Innovations III-22
Focus on Key Players III-22
ALTANA Pharma AG III-22
Boehringer Ingelheim III-22
B.Market Analytics III-23
Table 28: German Recent Past, Current and Future Analysis
for Asthma Therapeutics by Product Segment
Inhaled
corticosteroids, Short acting beta agonists, Long acting
beta agonists, Combinations, Anti- leukotrienes and Other
Asthma Therapeutics Markets Independently Analyzed by Annual
Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) III-23

Table 29: German 10-Year Perspective for Asthma Therapeutics
by Product Segment
Percentage Breakdown of Dollar Sales
for Inhaled corticosteroids, Short acting beta agonists,
Long acting beta agonists, Combinations, Anti- leukotrienes
and Other Asthma Therapeutics Markets for the Years 2000,
2006 and 2010 (includes corresponding Graph/Chart) III-24

4c. The United Kingdom III-25
A.Market Analysis III-25
Current & Future Analysis III-25
Product Launches/Innovations III-25
Strategic Developments III-26
Focus on Key Players III-26
AstraZeneca III-26
GlaxoSmithKline III-26
B.Market Analytics III-27
Table 30: UK Recent Past, Current and Future Analysis for
Asthma Therapeutics by Product Segment
Inhaled
corticosteroids, Short acting beta agonists, Long acting
beta agonists, Combinations, Anti- leukotrienes and Other
Asthma Therapeutics Markets Independently Analyzed by Annual
Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) III-27

Table 31: UK 10-Year Perspective for Asthma Therapeutics by
Product Segment
Percentage Breakdown of Dollar Sales for
Inhaled corticosteroids, Short acting beta agonists, Long
acting beta agonists, Combinations, Anti- leukotrienes and
Other Asthma Therapeutics Markets for the Years 2000, 2006
and 2010 (includes corresponding Graph/Chart) III-28

4d. Italy III-29
Market Analysis III-29
Current & Future Analysis III-29
Table 32: Italian Recent Past, Current and Future Analysis
for Asthma Therapeutics by Product Segment
Inhaled
corticosteroids, Short acting beta agonists, Long acting
beta agonists, Combinations, Anti- leukotrienes and Other
Asthma Therapeutics Markets Independently Analyzed by Annual
Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) III-29

Table 33: Italian 10-Year Perspective for Asthma
Therapeutics by Product Segment
Percentage Breakdown of
Dollar Sales for Inhaled corticosteroids, Short acting beta
agonists, Long acting beta agonists, Combinations, Anti-
leukotrienes and Other Asthma Therapeutics Markets for the
Years 2000, 2006 and 2010 (includes corresponding Graph/
Chart) III-30

4e. Spain III-31
Market Analysis III-31
Current & Future Analysis III-31
Table 34: Spanish Recent Past, Current and Future Analysis
for Asthma Therapeutics by Product Segment
Inhaled
corticosteroids, Short acting beta agonists, Long acting
beta agonists, Combinations, Anti- leukotrienes and Other
Asthma Therapeutics Markets Independently Analyzed by Annual
Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) III-31

Table 35: Spanish 10-Year Perspective for Asthma
Therapeutics by Product Segment
Percentage Breakdown of
Dollar Sales for Inhaled corticosteroids, Short acting beta
agonists, Long acting beta agonists, Combinations, Anti-
leukotrienes and Other Asthma Therapeutics Markets for the
Years 2000, 2006 and 2010 (includes corresponding Graph/
Chart) III-32

4f. Rest of Europe III-33
A.Market Analysis III-33
Current & Future Analysis III-33
Product Approvals/Launches III-33
Strategic Development III-34
Focus on Select Player III-34
Novartis Pharma AG (Switzerland) III-34
B.Market Analytics III-35
Table 36: Rest of Europe Recent Past, Current and Future
Analysis for Asthma Therapeutics by Product Segment -
Inhaled corticosteroids, Short acting beta agonists, Long
acting beta agonists, Combinations, Anti- leukotrienes and
Other Asthma Therapeutics Markets Independently Analyzed by
Annual Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) III-35

Table 37: Rest of Europe 10-Year Perspective for Asthma
Therapeutics by Product Segment
Percentage Breakdown of
Dollar Sales for Inhaled corticosteroids, Short acting beta
agonists, Long acting beta agonists, Combinations, Anti-
leukotrienes and Other Asthma Therapeutics Markets for the
Years 2000, 2006 and 2010 (includes corresponding Graph/
Chart) III-36

5. Rest of World III-37
A.Market Analysis III-37
Current & Future Analysis III-37
Product Launches III-37
Strategic Developments III-37
B.Market Analytics III-38
Table 38: Rest of World Recent Past, Current and Future
Analysis for Asthma Therapeutics by Product Segment -
Inhaled corticosteroids, Short acting beta agonists, Long
acting beta agonists, Combinations, Anti- leukotrienes and
Other Asthma Therapeutics Markets Independently Analyzed by
Annual Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) III-38

Table 39: Rest of World 10-Year Perspective for Asthma
Therapeutics by Product Segment
Percentage Breakdown of
Dollar Sales for Inhaled corticosteroids, Short acting beta
agonists, Long acting beta agonists, Combinations, Anti-
leukotrienes and Other Asthma Therapeutics Markets for the
Years 2000, 2006 and 2010 (includes corresponding Graph/
Chart) III-39

IV. COMPETITION

1. 3M Company (USA) IV-1
Table 40: First Quarter Sales Analysis: 2005-2006 (In
US$ billion) IV-5

Table 41: First Quarter Sales Analysis by Segment:
2005-2006 (In US$ billion) IV-5

Table 42: Annual Sales Analysis: 2004-2005 (In US$
billion) IV-5

Table 43: Annual Sales Analysis by Segment: 2004-2005
(In US$ billion) IV-5

Table 44: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ billion) IV-6
2. Abbott Laboratories (USA) IV-21
3. Able Laboratories, Inc. (USA) IV-30
4. Adams Respiratory Therapeutics (USA) IV-31
Table 45: Annual Sales Analysis: 2004-2006 (In US$
million) IV-31

Table 46: Annual Sales Analysis by Quarter: 2005-2006
(In US$ million) IV-32

Table 47: Annual Sales Analysis by Product: 2005-2006
(In US$ million) IV-32

Table 48: Annual Sales Analysis by Product: 2004-2005
(In US$ million) IV-32
5. Aerovance, Inc. (USA) IV-34
6. Almirall Prodesfarma SA (Spain) IV-35
7. Alpharma USPD, Inc. (USA) IV-37
8. Altana Pharma AG (Germany) IV-38
Table 49: Annual Sales Analysis: 2004-2005 (In €
billion) IV-39

Table 50: Annual Sales Analysis by Product Segment:
2004-2005 (In € billion) IV-39

Table 51: Annual Sales Analysis by Geographical Region:
2004-2005 (In € billion) IV-39
9. Amgen, Inc. (USA) IV-41
Table 52: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-42

Table 53: Annual Sales Analysis: 2004-2005 (In US$
million) IV-42

Table 54: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-42
10. Asthmatx, Inc. (USA) IV-45
11. Astrazeneca PLC (UK) IV-46
Table 55: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ Million) IV-48

Table 56: Half Yearly Sales Analysis By Quarter: 2005-
2006 (H1) (In US$ Million) IV-49

Table 57: Half Yearly Sales Analysis By Geographic
Region: 2005-2006 (H1) (In US$ Million) IV-49

Table 58: Annual Sales Analysis By Quarter: 2004-2005
(In US$ Million) IV-49

Table 59: Annual Sales Analysis By Geographic Region:
2004-2005 (In US$ Million) IV-49
Astrazeneca Pharmaceuticals LP (USA) IV-59
12. Biocon India Limited (India) IV-63
Table 60: Annual Sales Analysis: 2004-2005 (In INR
million) IV-64
13. Boehringer Ingelheim GmbH (Germany) IV-67
Boehringer Ingelheim Pharmaceuticals, Inc. (USA) IV-71
Boehringer Ingelheim Ltd. (Canada) IV-71
14. Breckenridge Pharmaceutical, Inc. (USA) IV-73
15. Cadila Pharmaceuticals Limited (India) IV-74
16. Cipla Ltd. (India) IV-77
17. Coley Pharmaceutical Group, Inc. (USA) IV-80
Table 61: Half-Yearly Sales Analysis: 2006-2005 (H1)
(In Can$ thousands) IV-80

Table 62: Quarterly Sales Analysis: 2005-2004 (In Can$
thousands) IV-81
18. Cosmobio Co., Ltd. (Japan) IV-82
19. Critical Therapeutics, Inc. (USA) IV-84
Table 63: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-84
20. deCODE Genetics (Iceland) IV-86
Table 64: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-87

Table 65: Annual Sales Analysis: 2004-2005 (In US$
million) IV-87

Table 66: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-87

Table 67: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-87
21. DMI BioSciences, Inc. (USA) IV-89
22. Dr. Reddys Laboratories (India) IV-90
Table 68: First Quarter Sales Analysis: 2005-2006 (Q1)
(In INR billion) IV-92

Table 69: Annual Sales Analysis: 2004-2005 (In INR
billion) IV-92

Table 70: Annual Sales Analysis by Segment: 2004-2005
(In INR billion) IV-93

Table 71: Annual Sales Analysis by Geographic Region:
2004-2005 (In INR billion) IV-93
23. Elan Corporation Plc (Ireland) IV-97
Table 72: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-98

Table 73: Annual Sales Analysis: 2004-2005 (In US$
million) IV-98

Table 74: Annual Sales Analysis By Segment: 2004-2005
(In US$ million) IV-98

Table 75: Annual Sales Analysis By Geographic Region:
2004-2005 (In US$ million) IV-99
24. Epitomics, Inc. (USA) IV-101
25. Eurodrug Laboratories Group (The Netherlands) IV-103
26. Exim Pharm International (India) IV-104
27. F. Hoffmann-La Roche Ltd. (Switzerland) IV-106
Table 76: First Quarter Sales Analysis: 2005-2006 (In
CHF billion) IV-107

Table 77: First Quarter Sales Analysis by Segment:
2005-2006 (In CHF billion) IV-107
Hoffmann-La Roche, Inc. (USA) IV-110
Genentech, Inc. (USA) IV-113
Table 78: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-115

Table 79: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) (Switzerland)) IV-115
28. Forest Laboratories, Inc. (USA) IV-119
Table 80: First Quarter Sales Analysis: 2006-2007 (In
US$ billion) IV-120

Table 81: Annual Sales Analysis: 2004-2006 (In US$
billion) IV-120

Table 82: Annual Sales Analysis by Product: 2005-2006
(In US$ billion) IV-120

Table 83: Annual Sales Analysis by Geographic Region:
2005-2006 (In US$ billion) IV-121

Table 84: Quarterly Sales Analysis: 2005-2006 (In US$
billion) IV-121
29. Gilead Sciences (USA) IV-125
Table 85: Half Yearly Sales Analysis by Quarter: 2005-
2006 (H1) (In USS$ million) IV-126

Table 86: Half Yearly Sales Analysis by Geographic
Region: 2005-2006 (H1) (In USS$ million) IV-126

Table 87: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-127

Table 88: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-127
30. Glaxosmithkline PLC (UK) IV-132
Table 89: Half Yearly Sales Analysis: 2005-2006 (H1)
(In £ million) IV-133

Table 90: Half Yearly Sales Analysis by Segment: 2005-
2006 (H1) (In £ million) IV-133

Table 91: Annual Sales Analysis by Segment: 2004-2005
(In £ million) IV-133
Glaxosmithkline (USA) IV-142
31. Glenmark Pharmaceuticals Ltd. (India) IV-145
Glenmark Pharmaceuticals SA (Switzerland) IV-145
32. GroPep Limited (Australia) IV-146
Table 92: Annual Sales Analysis by Business Segment:
2005-2006 (In A$ million) IV-148
33. Indoco Remedies (India) IV-150
34. Inflazyme Pharmaceuticals Limited (Canada) IV-153
35. Janssen-Cilag GmbH (Austria) IV-155
36. Kos Pharmaceuticals, Inc. (USA) IV-156
Table 93: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-157

Table 94: Annual Sales Analysis: 2004-2005 (In US$
million) IV-157
37. Kyorin Pharmaceutical Co., Ltd. (Japan) IV-159
38. Lab International, Inc. (Canada) IV-160
Table 95: Annual Sales Analysis by Business Segment:
2004-2005 (In Can$ million) IV-161

Table 96: Annual Sales Analysis by Geographic Region:
2004-2005 (In Can$ million) IV-161
39. Lark Laboratories (India) IV-164
40. MAP Pharmaceuticals, Inc. (USA) IV-166
41. Mayne Pharma Pty, Ltd. (Australia) IV-167
Table 97: Annual Sales Analysis By Segment: 2004-2005
(In A$ Million) IV-167

Table 98: Annual Sales Analysis By Geographic Region:
2004-2005 (In A$ Million) IV-168
42. MediciNova, Inc. (USA) IV-171
Table 99: Half-Yearly Sales Analysis: 2005-2006 (H1)
(In US$ Thousand) IV-171
43. Mercia Pharma, Inc. (USA) IV-175
44. Merck KGaA (Germany) IV-176
Table 100: Annual Sales Analysis Segment: 2004-2005 (In
€ million) IV-178
Merck & Co., Inc. (USA) IV-182
Table 101: Half Yearly Sales Analysis By Quarter: 2005
-2006 (H1) (In US$ million) IV-183

Table 102: Half Yearly Sales Analysis by Product: 2005
-2006 (H1) (In US$ million) IV-183

Table 103: Annual Sales Analysis by Product: 2004-2005
(In US$ million) IV-183

Table 104: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-184
Banyu Pharmaceutical Co., Ltd. (Japan) IV-186
Dey, L.P. (USA) IV-187
45. Millennium Pharmaceuticals, Inc. (USA) IV-189
Table 105: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-189

Table 106: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-189
46. MorphoSys AG (Germany) IV-192
Table 107: First Quarter Sales Analysis: 2005-2006 (Q1)
(In € million) IV-192
47. Neurim Pharmaceuticals (1991) Ltd. (Israel) IV-194
48. Nicholas Piramal India Ltd. (India) IV-195
Table 108: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-196
49. Novartis AG (Switzerland) IV-197
Table 109: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-200

Table 110: Half Yearly Sales Analysis by Segment: 2005
-2006 (H1) (In US$ million) IV-201

Table 111: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-201

Table 112: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-201
Novartis Pharma Switzerland AG (Switzerland) IV-209
Novartis Pharma GmbH (Germany) IV-210
Sandoz International GmbH (Germany) IV-210
50. Oriel Therapeutics, Inc. (USA) IV-212
51. Pfizer, Inc. (USA) IV-213
Table 113: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ billion) IV-215

Table 114: Half Yearly Sales Analysis by Segment: 2005
-2006 (H1) (In US$ billion) IV-215
Table 115: Half Yearly Sales Analysis by Geographic
Region: 2005-2006 (H1) (In US$ billion) IV-216
Pfizer Consumer Healthcare Division (USA) IV-220
52. Pharmaxis Ltd. (Australia) IV-224
53. Polyphor Limited (Switzerland) IV-226
54. Pure Pharma Limited (India) IV-228
55. Ranbaxy Laboratories Ltd. (India) IV-229
56. Rigel Pharmaceuticals, Inc. (USA) IV-243
Table 116: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-243

Table 117: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-244
57. Sanofi-Aventis (France) IV-245
Table 118: Half Yearly Sales Analysis: 2005-2006 (H1)
(In € million) IV-246

Table 119: Half Yearly Sales Analysis by Quarter: 2005
-2006 (H1) (In € million) IV-246

Table 120: Annual Sales Analysis: 2004-2005 (In €
million) IV-246

Table 121: Annual Sales Analysis by Segment: 2004-2005
(In € million) IV-246

Table 122: Annual Sales Analysis by Geographic Region:
2004-2005 (In € million) IV-247
Sanofi-Aventis (USA) IV-252
58. Schering-Plough Corporation (USA) IV-254
Table 123: Half Yearly Sales Analysis by Segment: 2005
-2006 (H1) (In US$ million) IV-255

Table 124: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-256

Table 125: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-256

Table 126: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-256
AESCA Pharma GmbH (Austria) IV-260
59. Sepracor, Inc. (USA) IV-261
Table 127: Half Yearly Sales Analysis by Quarter: 2005
-2006 (H1) (In US$ million) IV-261

Table 128: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-262
60. Shinpoong Pharmaceutical Co., Ltd. (South Korea) IV-265
61. SkyePharma PLC (UK) IV-266
Table 129: Half Yearly Sales Analysis by Segment: 2005
-2006 (H1) (In £ million) IV-267

Table 130: Annual Sales Analysis by Segment: 2004-2005
(In £ million) IV-267

Table 131: Annual Sales Analysis by Geographic Region:
2004-2005 (In £ million) IV-268
62. Sumit Laboratories (India) IV-271
63. Surya Pharmaceutical Ltd. (India) IV-272
64. Synairgen Research Limited (UK) IV-272
65. Tanabe Seiyaku Co., Ltd. (Japan) IV-273
Table 132: First Quarter Sales Analysis: 2006-2007 (Q1)
(In US$ million) IV-273
Table 133: First Quarter Sales Analysis by Business
Segment: 2005-2006 (Q1) (In Yen million) IV-274
Table 134: Annual Sales Analysis: 2005-2006 (In US$
million) IV-274

Table 135: Annual Sales Analysis by Business Segment:
2004-2005 (In Yen million) IV-274
66. TEVA Pharmaceutical Industries Ltd. (Israel) IV-277
Table 136: Half Yearly Sales Analysis by Quarter: 2005
-2006 (H1) (In US$ million) IV-278

Table 137: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-278
IVAX Corporation (USA) IV-287
Table 138: Nine Months Sales Analysis: 2004-2005 (Nine
Months Ended, September) (In US$ billion) IV-289

Table 139: Quarterly Sales Analysis: 2004-2005 (Nine
Months Ended, September) (In US$ billion) IV-289

Table 140: Nine Months Sales Analysis by Product
Category: 2004-2005 (Nine Months Ended, September) (In
US$ billion) IV-289

Table 141: Nine Months Sales Analysis by Geographical
Region: 2004-2005 (Nine Months Ended, September) (In
US$ billion)Limited (Israel)) IV-290
Ivax Laboratories, Inc. (USA) IV-295
67. Trudell Medical International (Canada) IV-296
68. UCB SA (Belgium) IV-297
Table 142: Annual Sales Analysis: 2004-2005 (In €
million) IV-297

Table 143: Annual Sales Analysis By Business Segment:
2004-2005 (In € million) IV-297
69. Zedawn Formulations (P) Ltd. (India) IV-300
70. Zenyth Therapeutics Limited (Australia) IV-301
Table 144: Annual Sales Analysis: 2004-2005 (In A$
million) IV-301